CommercialPrior AuthMedium impact
Rolvedon (eflapegrastim-xnst)
Blue Cross & Blue Shield of Mississippi·MS · Oncology, Hematology·Medical Policy
We identified it
Jun 20, 2026
Summary
BCBS Mississippi has updated their policy stating that Rolvedon (eflapegrastim-xnst), a cancer drug used to prevent infections during chemotherapy, is considered not medically necessary due to available formulary alternatives. Claims for this medication will be denied without prior authorization approval through BCBSMS PA review process.
Action Required
Immediately: Billing team must obtain prior authorization through BCBSMS PA review process before administering or billing for Rolvedon (eflapegrastim-xnst) injections using code J1449. Update billing system to flag this code for prior auth requirement. Consider alternative formulary G-CSF medications for cancer patients. Claims submitted without prior authorization will be denied as not medically necessary.